Veraxa Biotech AG - Post De-SPAC current report, Q3 FY2026

Business Context and Reporting Period

Veraxa Biotech AG, a foreign private issuer based in Zurich, Switzerland, filed Form 6-K for the month of August 2026. The filing reports on a strategic research collaboration with Secarna Pharmaceuticals GmbH & Co. KG focused on developing next-generation antibody oligonucleotide conjugates (AOCs) for autoimmune and chronic immune diseases.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure regarding research milestones and does not contain financial statements.

Material Changes

The primary material change is the announcement of initial positive results from the AOC alliance with Secarna Pharmaceuticals. No financial comparisons to prior periods are included in this document.

Outlook, Risks, and Management Commentary

Management highlighted the successful initial results of the collaboration as a significant step in their pipeline for treating autoimmune conditions. The filing incorporates a press release (Exhibit 99.1) detailing these findings. No specific forward-looking financial guidance, risk factors, or contingencies are detailed within the text of this specific Form 6-K.

Investor Verification Checklist

  • Verify the specific clinical or pre-clinical data points in the attached press release (Exhibit 99.1) regarding the AOC results.
  • Confirm the terms and financial obligations of the collaboration agreement with Secarna Pharmaceuticals.
  • Review the company's most recent Form 20-F for updated financial position and cash runway, as this filing contains no financial data.
  • Assess the timeline for subsequent development phases following these initial positive results.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.